AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER

被引：0
|
作者：
Gerardi, C. [1 ]
Floriani, I. [1 ]
Biagioli, E. [1 ]
D'Incalci, M. [1 ]
Fossati, R. [1 ]
Colombo, N. [2 ]
机构：
[1] IRCCS Ist Ric Farmacol Mario Negri Milano, Milan, Italy
[2] Univ Milano Bicocca, Dipartimento Sci Chirurg, Milan, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-1249
引用
收藏
页码：455 / 456
页数：2
相关论文
共 50 条
  • [31] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J., II
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    Schmelter, T.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 70 - 76
  • [32] Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Dominique Koensgen
    Dirk Stengel
    Antje Belau
    Peter Klare
    Guelten Oskay-Oezcelik
    Thomas Steck
    Oumar Camara
    Alexander Mustea
    Harald Sommer
    Alexandra Coumbos
    Thomas Bogenrieder
    Werner Lichtenegger
    Jalid Sehouli
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 393 - 400
  • [33] A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)
    Fujiwara, Hiroyuki
    Ushijima, Kimio
    Nagao, Shoji
    Takei, Yuji
    Shimada, Muneaki
    Takano, Masashi
    Yoshino, Kiyoshi
    Kawano, Yoshiaki
    Hirashima, Yasuyuki
    Nagase, Satoru
    Nishio, Shin
    Nishikawa, Tadaaki
    Ito, Kimihiko
    Shoji, Tadahiro
    Kimura, Eizo
    Takano, Tadao
    Sugiyaman, Toru
    Kigawa, Junzo
    Fujiwara, Keiichi
    Suzuki, Mitsuaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (10) : 1284 - 1291
  • [34] Randomized phase III study comparing paclical-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Vergote, Ignace
    Brize, Arija
    Lisyanskaya, Alla Sergeevua
    Lichinitser, Mikhail
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
    Tadahiro Shoji
    Shinichi Komiyama
    Junzo Kigawa
    Hiroshi Tanabe
    Kazuyoshi Kato
    Hiroaki Itamochi
    Hiroyuki Fujiwara
    Shoji Kamiura
    Tetsutaro Hamano
    Toru Sugiyama
    BMC Cancer, 18
  • [36] An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
    Shoji, Tadahiro
    Komiyama, Shinichi
    Kigawa, Junzo
    Tanabe, Hiroshi
    Kato, Kazuyoshi
    Itamochi, Hiroaki
    Fujiwara, Hiroyuki
    Kamiura, Shoji
    Hamano, Tetsutaro
    Sugiyama, Toru
    BMC CANCER, 2018, 18
  • [37] A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma
    Selle, F.
    Sevin, E.
    Ray-Coquard, I.
    Mari, V.
    Berton-Rigaud, D.
    Favier, L.
    Fabbro, M.
    Lesoin, A.
    Lortholary, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2191 - 2196
  • [38] Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
    Chong, W. Q.
    Low, J. L.
    Sooi, K.
    Soo, R. A.
    Le, C.
    Teo, H. L.
    Samol, J.
    Goh, G.
    Kong, L. R.
    DasGupta, R.
    Chia, S.
    Wong, R.
    Gopinathan, A.
    Tay, J. K.
    Eu, D.
    Tsang, R.
    Loh, K-S.
    Tai, B. C.
    Lim, Y. C.
    Goh, B-C.
    ANNALS OF ONCOLOGY, 2024, 35 : S614 - S614
  • [39] OPSALIN: A phase II placebo-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer treated with carboplatin (Cb) and paclitaxel (P).
    Pujade-Lauraine, Eric
    Vergote, Ignace B.
    Allard, Aurore
    Rey, Augustin A.
    Sessa, Cristiana
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
    Kaye, S. B.
    Poole, C. J.
    Danska-Bidzinska, A.
    Gianni, L.
    Del Conte, G.
    Gorbunova, V.
    Novikova, E.
    Strauss, A.
    Moczko, M.
    McNally, V. A.
    Ross, G.
    Vergote, I.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 145 - 152
12345